Ticker: LQDA

Snapshot - Liquidia Corporation (NASDAQ: LQDA) What's happening inside: FDA approved YUTREPIA on May 23, 2025 and Liquidia commercially launched it on June 2, 2025. The company has moved from R&D focus into commercialization (hiring, inventory build, sales shipments) and drew additional funding u...

Liquidia Technologies (LQDA) shares surged 9.6% after announcing the commercial shipment of YUTREPIA™, a treatment for pulmonary hypertension. A favorable court ruling further enhances investor confidence, marking a key milestone for the company.

Liquidia Corporation (NASDAQ: LQDA) faced a 40% stock drop after the FDA delayed approval for its inhaled drug yutrepia due to United Therapeutics' exclusivity on Tyvaso DPI. The situation highlights the volatility in biopharma investments amid patent disputes.